Clinical practice pancreatic enzyme replacement therapy in cystic fibrosis: Australian guidelines

Anthony, H., Collins, C. E., Davidson, G., Mews, C., Robinson, P., Shepherd, R. W. and Stapleton, D. (1999) Clinical practice pancreatic enzyme replacement therapy in cystic fibrosis: Australian guidelines. Journal of paediatrics and child health, 35 2: 125-129. doi:10.1046/j.1440-1754.1999.00363.x

Author Anthony, H.
Collins, C. E.
Davidson, G.
Mews, C.
Robinson, P.
Shepherd, R. W.
Stapleton, D.
Title Clinical practice pancreatic enzyme replacement therapy in cystic fibrosis: Australian guidelines
Journal name Journal of paediatrics and child health   Check publisher's open access policy
ISSN 1034-4810
Publication date 1999-04-01
Sub-type Article (original research)
DOI 10.1046/j.1440-1754.1999.00363.x
Open Access Status Not yet assessed
Volume 35
Issue 2
Start page 125
End page 129
Total pages 5
Editor John M. Court
Place of publication Victoria, Australia
Publisher Royal Australasian College of Physicians
Language eng
Subject C1
321019 Paediatrics
730204 Child health
Abstract Pancreatic enzyme replacement therapy (PERT) is a major factor associated with achieving optimum growth and nutritional status in cystic fibrosis (CF) patients with pancreatic insufficiency and consequent malabsorption. Currently in Australian CF clinics policies for the usage of PERT vary considerably. This paper highlights the current issues related to fat absorption and use of PERT in CF. It also provides evidence to support the recommendation of a PERT dose based on a standard ratio of lipase units per gram of dietary fat consumed for individual patients. A consistent approach to PERT doses will facilitate identification of patients whose PERT intake increases their risk of fibrosing colonopathy and for whom gastroenterological review is warranted. Recent reports indicate that PERT intake can be reduced with a secondary improvement in growth and nutrition status as a consequence of increased dietetic input. These Australian guidelines for the judicious use of PERT in CF should lead not only to a refinement in nutritional management of patients with CF but should also facilitate an improvement in compliance with therapy due to sophistication in patient education materials. The Australian guidelines for the use of PERT in CF if correctly applied, will also provide patients and their families with a better understanding of the relationship between PERT and nutritional status.
Keyword cystic fibrosis
pancreatic enzymes
clinical practice guidelines
Q-Index Code C1

Document type: Journal Article
Sub-type: Article (original research)
Collection: School of Medicine Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 24 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 34 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Wed, 11 Jun 2008, 00:55:31 EST